According to data from the Federal Reserve, the average American household had a net worth of $1.06 million in 2022, the last ...

Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they ...

New research led by an Emory oncologist links obesity to rising cancers in young adults and shows that losing 10% of body ...

The benchmarks for height and weight in a Packers cornerback are well established, but body types and proportions arguably ...

GRAND FORKS — North Dakota has the fifth-lowest childhood obesity rates in the country, but the state's obesity rates ...

It's normal to feel tired from time to time—a bad night of sleep, stress, travel, and more can leave you yawning your way ...

To figure out where consumers can get the best bang for their buck and not miss out on a meat indulgence, The Post looked at ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. When it comes to achieving a healthy body weight, some men ...

With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries ...

The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli ...

Eli Lilly's next-generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight.

Eli Lilly 3rd-generation GLP-1 retatrutide lowers A1C by 1.9% and reduces body weight by 33.3 pounds in phase 3 trial.